Alcohol-associated liver disease
Open accessThe DOI matches its Crossref record; 199 of the 202 references it cites were found in a registry or an index.
Abstract
Alcohol-associated liver disease (ALD) is a major cause of chronic liver disease worldwide, and comprises a spectrum of several different disorders, including simple steatosis, steatohepatitis, cirrhosis, and superimposed hepatocellular carcinoma. Although tremendous progress has been made in the field of ALD over the last 20 years, the pathogenesis of ALD remains obscure, and there are currently no FDA-approved drugs for the treatment of ALD. In this Review, we discuss new insights into the pathogenesis and therapeutic targets of ALD, utilizing the study of multiomics and other cutting-edge approaches. The potential translation of these studies into clinical practice and therapy is deliberated. We also discuss preclinical models of ALD, interplay of ALD and metabolic dysfunction, alcohol-associated liver cancer, the heterogeneity of ALD, and some potential translational research prospects for ALD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In ALD, hepatocyte cell death results in the release of DAMPs that, together with gut-derived PAMPs, activate surrounding immune cells and serve as recruiting signals for circulating immune cells [82, 83].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [82]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358 · cited 1×
“Alcohol-associated cirrhosis causes an estimated 25% of global deaths due to liver cirrhosis and up to 40% in certain areas of Europe (146).”
BackgroundMarrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,539 · cited 1×
“Cirrhosis is a necessary intermediate step for A-HCC development and amplifies the overall risk for carcinogenesis in patients with ALD (157, 158).”
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100 · cited 1×
“…liver disease, which encompasses all types of fatty liver diseases, now termed MASLD, which replaces the stig-matizing “nonalcoholic fatty liver disease” (NAFLD), and a new category, called MetALD, which includes patients with MASLD who also have significant alcohol consumption (143, 144).”
Global burden of liver disease: 2023 update
Devarbhavi, H., Asrani, S. K., Arab, J. P., Nartey, Y. A., Pose, E., & Kamath, P. S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.017 · Cited by 2,267
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
Gao, B., & Bataller, R. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.09.002 · Cited by 1,963
Self-citationResolving the fibrotic niche of human liver cirrhosis at single-cell level
Ramachandran, P., Dobie, R., Wilson-Kanamori, J. R., Dora, E. F., Henderson, B. E. P., Luu, N. T., Portman, J. R., Matchett, K. P., Brice, M., Marwick, J. A., et al. (2019) · Nature · doi:10.1038/s41586-019-1631-3 · Cited by 1,784 · cited 1×
“Indeed, by utilizing scRNA-Seq analysis, two studies have identified new cell subpopulations that drive fibrosis and inflammation in the mouse AH model and human alcohol-as-sociated cirrhosis (120, 121).”
The gut-liver axis and the intersection with the microbiome
Tripathi, A., Debelius, J., Brenner, D. A., Karin, M., Loomba, R., Schnabl, B., & Knight, R. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0011-z · Cited by 1,480 · cited 1×
“Moreover, alcohol misuse and ALD are associated with small intestinal bacterial overgrowth, alterations of gut microbiota (“dysbiosis”), and bacterial translocation (46, 47).”
BackgroundPathophysiology of Inflammatory Bowel Diseases
Chang, J. T. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2002697 · Cited by 1,295
Seitz, H. K., Bataller, R., Cortez-Pinto, H., Gao, B., Gual, A., Lackner, C., Mathurin, P., Mueller, S., Szabo, G., & Tsukamoto, H. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0014-7 · Cited by 1,271
Self-citationMouse model of chronic and binge ethanol feeding (the NIAAA model)
Bertola, A., Mathews, S., Ki, S. H., Wang, H., & Gao, B. (2013) · Nature Protocols · doi:10.1038/nprot.2013.032 · Cited by 1,213 · cited 1×
“In 2010, we introduced binge ethanol intake into the chronically ethanol-fed mice, which causes significant neutrophil infiltration and liver injury (23, 133).”
Self-citation
Cited by
Items 201–300 of 361
Yuan, Q., Chen, Z., Sun, B., Zheng, C., Kang, Y., Lou, Y., & Zheng, M. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1675607 · Cited by 2
Role of SQSTM1/p62 in regulating Mallory-Denk body in alcohol-associated liver disease
Hinz, K., Qian, H., Peiffer, B. J., Sun, Z., Ni, H., & Ding, W. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100262 · Cited by 1
Song, Y., Liu, M., Zhou, M., Ren, X., Feng, B., & Xie, Y. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115858 · Cited by 1
Niu, X., Ma, L., Zhou, Z., Li, Y., Shi, A., Weng, L., & Xing, H. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112988 · Cited by 1
Zhu, F., Fan, F., Jiang, C., Zhang, L., Ali, M. H., Wang, Y., Zhang, K., Zhao, Z., Li, Q., Li, S., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115881 · Cited by 1
Xia, J., Tang, X. P., Zhu, Q., & Xu, Y. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00043-x · Cited by 3
Szczerbińska, A., Roliński, J., Surdacka, A., & Cichoż‐Lach, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311717 · Cited by 1
“Understanding the mechanisms by which CXCLs contribute to ALD is crucial for developing future targeted therapies and improving diagnostic and prognostic strategies [22–24].”
Zhou, Q., Ma, X., Cui, Q., Zhang, L., Yao, C., Zhang, Z., Wang, X., & Chu, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1714502 · Cited by 1
“Despite decades of research elucidating the downstream pathological events — such as metabolic reprogramming, oxidative stress, and sterile in fl ammation — therapeutic progress has been profoundly limited (5, 6).”
Singh, M. M., Shahi, A., Chaturvedi, C. P., Rajak, S., Yadav, A. K., Kumar, A., Gupta, A. K., & Sinha, R. A. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.153072 · Cited by 2
Zhang, W., Qi, M., Zhao, X., Zhong, Y., Xu, W., Sheng, L., & Yang, L. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.124151 · Cited by 1
Huang, J., Wang, J., Wang, X., Yang, W., Zhou, H., Cui, R., Zeng, S., Shao, R., Jin, R., Zhang, Y., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.116040 · Cited by 1
Cai, W., Wang, P., Zhang, R., Dong, L., Li, J., Wang, M., Wang, L., Shao, X., Jing, T., Hu, Y., et al. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.71435 · Cited by 1
Lu, S., Huang, Y., Li, S., Wang, Z., Wang, N., Guo, Q., Piao, H., Ji, W., & Dong, W.-W. (2026) · Food Frontiers · doi:10.1002/fft2.70230 · Cited by 1
Gao, W., Lin, Z., Bao, Y., Liu, M., Ma, G., Chen, X., Yu, S., & Zeng, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1711388 · Cited by 2
“This syndrome manifests as a pathological spectrum that extends from simple steatosis to cirrhosis and hepatocellular carcinoma (3, 4).”
Huang, N.-F., Ling, P., Xu, Y.-J., Feng, X., Zheng, Y., & Sun, T. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i8.115077 · Cited by 1
Wei, X., Wang, Z., Wang, J., Yang, H., Zhou, F., Qi, S., Zhang, J., Shi, X., Xu, G., Li, Z., et al. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121476 · Cited by 1
Hepatocyte CEBPA-ORM1 axis restricts alcohol-associated liver disease
Yan, N., Xia, Y., Zhang, Y., Sawaswong, V., Xu, X., Saito, Y., Nanduri, R., Dai, M., Aibara, D., Krausz, K. W., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001737 · Cited by 2
A preclinical candidate of cyclophilin D inhibition improves alcohol-associated liver injury
Che, Z., Luo, Z., Xiao, D., Ma, F., Zhou, H., Song, Y., Guo, S., Yuan, Y., Wang, H., Mak, C., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102654 · Cited by 1
Zhang, X., Xu, Z., You, Y., Xie, L., Jiang, Y., Chen, J., Xu, Z., Xu, F., & Zhou, D. (2026) · PLoS ONE · doi:10.1371/journal.pone.0344960 · Cited by 1
“Alcohol-associated liver disease (ALD) is a syndrome that includes a range of findings from simple liver steatosis to steatohepatitis, followed by progressive alcoholic liver fibrosis and cirrhosis, chronic hepatitis, and finally, extensive hepatocyte necrosis or liver cancer [1,2].”
Aquaporin 9 regulates acetaldehyde uptake, alcohol‐induced liver injury, and drinking behavior
Chen, C., Mackowiak, B., Feng, D., Guan, Y., Lin, Y., Fu, Y., Wei, S., Zhang, L., Kunos, G., & Gao, B. (2026) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.70272 · Cited by 1
Self-citationLetter: Unmasking the Risks—The Need for Robust Data on Baclofen in Cirrhotic Patients
Salman, Z. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70693 · Cited by 1
Gu, Z., Meng, S., Yao, B., Gao, B., Chen, S., Ren, F., Li, P., Shao, T., & Shang, N. (2026) · Nature Communications · doi:10.1038/s41467-026-72211-3 · Cited by 2
Self-citationEpithelial MLCK deficiency alleviates alcohol-associated liver disease via dendritic–Th17 cell axis
Wang, X., Wang, J., Xiong, L., Tang, S., Wu, S., Zhao, J., Wang, Z., Zhu, J., Li, Y., Zhuang, J., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101849 · Cited by 1
Secondary Immune Surveillance via upregulation of C-type lectin receptors
Patel, F., Boafo, E., Zheng, Y., Varnet, C., & Kim, A. (2026) · npj gut and liver. · doi:10.1038/s44355-026-00067-x · Cited by 1
Extracellular matrix stiffness in chronic liver disease: From mechanisms to treatments
Xi, Z.-H., Sun, W.-J., Li, M., Dong, Q.-Q., Dong, X., Qiao, Z.-L., Tao, H., Yang, J., & Lu, C. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118194 · Cited by 1
Wang, H., Ding, W., Zhang, L., Xu, M., & Sui, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135809 · Cited by 1
“Alcohol-associated liver cirrhosis (ALC) represents the end-stage of alcohol-related liver disease, contributing disproportionately to global cirrhosis-related mortality [1,2].”
Nandagopal, P. B., Munieswaran, G., & Manickam, V. (2026) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2026.1892336 · Cited by 1
“Alcohol-associated liver disease (ALD) represents a progressive spectrum of hepatic injury driven by interconnected processes including metabolic dysfunction, chronic inflammation, oxidative stress and fibrotic remodelling (Mackowiak et al., 2024; Mandrekar and Mandal, 2024).”
Contemporary global epidemiology of cirrhosis
Saokhieo, P., Auttapracha, T., Danpanichkul, P., Pang, Y., Yang, L., Singal, A. G., Kim, D., & Wijarnpreecha, K. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000989 · Cited by 2
“[ 53 ] Between 1999 and 2022, age-adjusted mortality from ALD among individuals under 55 rose significantly from 3.9 to 9.7 per 100,000 population, highlighting a growing public health burden among younger and middle-aged adults.”
InfluentialZhang, X.-Y., Chen, Q.-J.-J., Zhu, F., Li, M., & Shang, D. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i37.4163 · Cited by 1
Azar, K. A. H. M., Ezhilarasan, D., Karthick, M., Harini, K. S., & Kumar, V. (2024) · Environmental Toxicology · doi:10.1002/tox.24465 · Cited by 2
BRISC inactivation alleviates alcohol-induced liver injury in mice
Wang, T., Zhang, W., Liu, X., Liu, K., Ren, G., Xiang, S., Zhan, Y., Chen, H., Gao, H., Zhao, K., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-89796-2 · Cited by 2
Rodríguez-Negrete, E. V., García‐Machorro, J., Madrigal‐Santillán, E., Morales‐González, Á., & Morales‐González, J. A. (2025) · Gastroenterology Insights · doi:10.3390/gastroent16020013 · Cited by 2
“Reports found in the literature demonstrate the damage to the liver caused by alcohol consumption [12–15], but the damage or alterations caused by weekend alcohol consumption to the liver have not been described to date; in particular, there are no reports on changes in the activity of antioxidant…”
Jiamutai, F. N. U., Hatfield, A., Herbert, A., Majumdar, D., Shankar, V., & Lackey, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-07569-3 · Cited by 1
Wang, Z.-H., Jiang, Y., Fang, T., Li, J.-Q., Wang, T., Zhou, C.-Y., Wang, R., Cai, W.-T., & Liu, H. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1577424 · Cited by 1
Shining light on liquid–liquid phase separation in chronic liver disease
Li, M., Yang, Y., Dong, Q.-Q., Sun, W.-J., Tao, H., & Yang, J. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104464 · Cited by 1
Dong, H. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47030160 · Cited by 1
Liver immunology: new insights from cutting-edge technologies
Guillot, A., & Gao, B. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01342-2 · Cited by 1
Self-citationYimgoua, E. S., Kenfack, C. M., Feussom, N. G., Fassi-Kadji, J. B., Nkondo, E. T., Femoe, U. M., Tchuenté, L.-A. T., & Jatsa, H. B. (2025) · medRxiv · doi:10.1101/2025.10.28.25338939 · Cited by 1
Kennedy, L. L. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.03.014
Mykytenko, A. О., Akimov, O. Y., Yeroshenko, G. А., & Непорада, К. С. (2024) · World of Medicine and Biology · doi:10.26724/2079-8334-2024-2-88-211-215
Choday, S., Zahdeh, T., Paul, K., Reynolds, J. A., & Wong, R. J. (2024) · Research Square · doi:10.21203/rs.3.rs-5301471/v1
Heringer, D. L., Costa, G. P. A., Weleff, J., Rodrigues, V., Sengupta, S., & Anand, A. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101742
Prospects of elafibranor in treating alcohol-associated liver diseases
Cui, W.-T., Xue, H.-R., Wei, D.-F., Feng, X.-Y., & Wang, K. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i2.99549
Wu, B., Weng, X., Pan, Y., Tian, Z., Wu, P., Shao, J., Liu, Y., Huang, R., Xu, T., & Zhou, K. (2024) · Journal of Human Genetics · doi:10.1038/s10038-024-01313-x
Alcohol Plus Additional Risk Factors: Rodent Model of Liver Injury
Wu, Q., Yang, D., Liu, C., & Xu, T. (2024) · Seminars in Liver Disease · doi:10.1055/a-2490-4278 · Cited by 1
Vetlugina, T. P., Epimakhova, E. V., Prokopieva, V. D., Nikitina, V. B., Исаевна, М. А., & Bokhan, N. A. (2025) · Psikhiatriya · doi:10.30629/2618-6667-2024-22-5-49-58 · Cited by 1
Molecular Insights: Gene Expression in HCC and Testicular Cancer among ALD Patients.
Fatima, H., Maqbool, H., Ahmad, H., & Sheikh, N. (2024) · Albus Scientia · doi:10.56512/as.2024.2.e241231
Gellée, N., Legrand, N., Jouve, M., Devaux, P.-J., Dubuquoy, L., & Sobolewski, C. (2025) · Cancers · doi:10.3390/cancers17030348
Effect of long-term moderate red wine consumption in CD1 female mice
García-Moruno, E., Blázquez, A.-B., de Oya, N. J., Esteban, A., Motta, S., Costantini, A., Sánchez‐Cordón, P. J., Pericuesta, E., Martín-Acebes, M. A., Gutiérrez‐Adán, A., et al. (2025) · Food & Function · doi:10.1039/d5fo00435g
Research Progress on Pathological Mechanisms of Liver Injury and Nutritional Intervention Strategies
李, 辉. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.153645
Alcohol liver disease: societal contributing factors and treatment options
Toop, A. (2025) · Gastrointestinal Nursing · doi:10.12968/gasn.2025.0012
Xi, Y., Guo, D., Shi, L., Guo, J. Q., Chen, X., Tang, J., & Zhou, C. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i13.104546
Niu, M., & Ding, W. (2025) · Gut · doi:10.1136/gutjnl-2025-335116 · Cited by 1
Qu, X.-H., & Liu, X. (2025) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v33.i5.389
Feng, Q., Manousou, P., Izzi‐Engbeaya, C. N., & Woodward, M. (2025) · Liver international communications. · doi:10.1002/lci2.70019
Kv1.3 knockdown attenuates alcohol-related liver injury in mice through induction of tryptamine
Wang, H., Xia, G., Ke, T., Chen, X.-X., Zhen, W.-J., Tian, Y.-Y., Chen, S., Cheng, Z., Li, J., Zhang, L., et al. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01544-4 · Cited by 3
Skvortsov, V. V., Kolomytsev, V. V., & Владимировна, Г. Л. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-193
Fetuin-A Can Assess the Severity of Alcohol-Related Liver Disease
Salmanoğlu, M., Küçük, İ., & Baş, S. (2025) · Medicina · doi:10.3390/medicina61071147
“A long duration of ethanol use can exert severe liver injury and fibrogenic effects seen in AC patients, as expected [2].”
InfluentialHu, B., Xia, H., Tian, P., Li, X.-B., Yang, Y., Zhu, Z., Zhou, Y., Liao, W., Wang, S., Yang, L., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136104 · Cited by 3
Yadav, M., Gupta, A., Yadav, S., Sharma, V., Magar, Y., Deepanshu, D., Khan, T., Sharma, N., Yadav, K., Sharma, N., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.02.662754
Yang, G., Li, B., Chen, J., Wei, C., You, W., Pan, C., Liu, T., Zhao, Y., Zhang, M., Sun, C., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5317607
Hepatitis patients undergoing cardiac surgery: A single-center retrospective study
Ju, J.-L., Yao, Y.-T., Li, J., Cheng, Z., Fan, L.-L., Zhong, Y.-L., & The Evidence in Cardiovascular Anesthesia (EICA) Group (2025) · Medicine · doi:10.1097/md.0000000000043326
“Alcoholic liver disease causes damage to hepatocytes, [13] which reduces the synthesis of coagulation factors and is associated with thrombocytopenia and dysfunction.”
Thakurdesai, A., Kumari, A., Shay, H., Elgharabawy, K., Winrich, E. J., Zhang, W., Jackson, A., Cave, M. C., Kong, M., Zhang, X., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176157
“Additionally, their diets often lack essential micronutrients, such as zinc and magnesium [4,18,19].”
MANAGEMENT OF ALCOHOLIC LIVER DISEASE (ALD): A REVIEW
bano, Y., Agrrwal, N., Rathia, S., Chandravanshi, L., & sahu, D. (2025) · International Ayurvedic Medical Journal · doi:10.46607/iamj2013082025
Park, J. B., & Peters, R. C. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1661468
“For example, nonalcoholic fatty liver disease (NAFLD) has been reported to ensue with exposure to drugs, alcohol, pesticides and pollutants (25–27).”
InfluentialHoppe, C., Hönes, G. S., Prinz, A. D., Siemes, D., Wenzek, C., Grund, S. C., Schörding, A.-K., Machlah, Y. M., Bruinstroop, E., Laehnemann, D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.10.681680
Research Progress on Muscle, Fat and Adverse Liver Outcomes
张, 雨. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15103004
Guo, C., Wang, Y., Chen, Y., Yang, X., Deng, G., Liang, L., Zhang, T., Hua, B., & Qiu, L. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04754-z
Gallegos, E. M., Couvillion, K. E., & Simon, L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-34258-5.00004-9
Loftis, J. M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29090-9.00006-4
Insulin Growth Factor Binding Protein-6 and the Liver
Coda, A. R. D., Kasperczyk, S., Dobrakowski, M., Kasperczyk, A., Trecca, M. I., Liso, A., Serviddio, G., & Bellanti, F. (2026) · Cells · doi:10.3390/cells15010077
Yadav, M., Gupta, A., Yadav, S., Sharma, V., Magar, Y., Deepanshu, D., Khan, T., Sharma, N., Yadav, K., Sharma, N., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.118984
Li, Y., Guo, R., Qian, Y., Hawro, I., Córdoba‐Chacón, J., Jiang, Y., & Song, Z. (2026) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00379.2025
Role of myeloid cell transcription factor EB in alcohol-induced liver injury in mice
Williams, S. N., Yusuf, K., Chao, X., Ni, H., & Ding, W. (2026) · Liver Research · doi:10.1016/j.livres.2026.01.003
“2 – 4 ALD has been extensively connected to the increased occurrence of liver cirrhosis and hepatocellular carcinoma, labeling it as one of the leading causes of death associated with these debilitating liver diseases.”
Machado, C. M., & Aguiar, P. (2026) · Acta Médica Portuguesa · doi:10.20344/amp.24100
From liver to vasculature: An integrated view of cardiovascular risk in hepatic steatosis
Hu, X., & Long, L. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156550
Interleukin-38: A Candidate Biomarker for Disease Severity in Advanced Steatotic Liver Disease
Wagner, V., Mederer, M., Enrich, B., Cibulkova, V., Piater, J., Zollner, A., Giquel-Fernandes, R., Tilg, H., & Effenberger, M. (2026) · Cells · doi:10.3390/cells15030280
“…by alcohol-induced cellular stress and disruption of the gut– liver axis with increased translocation of bacterial products and endotoxin exposure [4,5], whereas in MASLD, visceral adipose tissue dysfunction, insulin resistance, lipotoxicity, and chronic low-grade systemic inflammation critically…”
Post-Translational Changes in Serum Albumin in Patients with Alcohol-Associated Hepatitis
Montomoli, J., Baldassarre, M., Sandahl, T. D., Naldi, M., Glavind, E., Pompili, E., Jepsen, P., Palmese, F., Caraceni, P., Vilstrup, H., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031503
“…in patients hospitalized with AH, based on the hypothesis that these post-translational modifications are driven by the complex interplay between severe oxidative stress, the intense systemic inflammatory response, and the metabolic derangements characteristic of this condition [13].”
Savoca, M. T., Takemoto, K., Hu, J., Li, L., Zhong, Z., & Lemasters, J. J. (2026) · Toxicological Sciences · doi:10.1093/toxsci/kfag013 · Cited by 1
Liu, T., Li, C. G., Zhang, G. X., Liu, L., Li, W., Wang, L., & Du, P. (2026) · Food Nutrition · doi:10.1016/j.fnutr.2026.100057
Moon, S. Y., Baek, Y.-H., Kang, D., Lee, J., Kang, Y. W., Son, M., Liu, H., Lee, S. S., & Park, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-40073-w
Fehér, D. L., Al-Omari, A., Sándor, Z., Hegedüs, D., Gaszner, B., Szombati, V., Fincsúr, A., & Kormos, V. (2026) · Cells · doi:10.3390/cells15050423
“Intermediates, as well as by-products, of alcohol metabolism damage the liver through several mechanisms, such as inhibiting lipid metabolism, increasing inflammatory processes, and triggering fibrosis, which can ultimately lead to alcoholic liver disease (ALD) [2].”
Xie, J., Liu, S., Xu, Y., Song, B., Liu, J., Du, G., Xie, L., & (23863), W. C. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.174791
Santra, A., Gouthami, K., Maity, S., Surtineni, V. P., Nagajyothi, P. C., Shim, J., Arjunan, S., & Reddy, V. D. (2026) · Advances in Natural Sciences Nanoscience and Nanotechnology · doi:10.1088/2043-6262/ae4fbf
Wu, X., Zhang, Q., Wang, Q.-Q., Liu, Z.-N., Ni, Y., Liu, X., & Lv, X. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.151409
Salmanoğlu, M., Baş, S., Armutcuoglu, Y. K., & Küçük, İ. (2026) · Anatolian Current Medical Journal · doi:10.38053/acmj.1848023
Genetic regulation of AIF1 shapes immune and liver injury profiles in chronic alcohol use
Antonello, P. C., Hodgkinson, C. A., Feng, D., Marietta, C. A., Krishnan, B. M., Parra, M. A., Sun, Z., Gao, B., Goldman, D., & Antoine, M. W. (2026) · JCI Insight · doi:10.1172/jci.insight.198209 · Cited by 1
Self-citationNeutrophils in Liver Diseases: Functions and Challenging Therapies
Ma, R., Meng, H., Chen, X. H., Shen, H., Zuo, L., & Wang, H. (2026) · Seminars in Liver Disease · doi:10.1055/a-2847-3228
Na, H. S., Hwang‐Bo, J., Shin, W.-C., Jang, J., Choi, B. R., & Lee, D. (2026) · Antioxidants · doi:10.3390/antiox15040461
“AILD is a major public health concern, representing a common form of chronic alcohol-induced liver disease that progresses from simple steatosis to alcoholic hepatitis, hepatic fibrosis and cirrhosis, and ultimately hepatocellular carcinoma [1].”
Thakuri, L. S., Sonar, N. S., Park, H. B., Subedi, L., Phuyal, S., Kang, K.-H., Kang, H. W., Park, J. W., Lee, M., & Rhyu, D. Y. (2026) · Asian Pacific Journal of Tropical Biomedicine · doi:10.4103/apjtb.apjtb_751_25
Li, Q., Liu, Y., Shan, S., Wen, Y., Wu, X., Xie, S., Liu, B., Zhao, C., & Chen, W. (2026) · Antioxidants · doi:10.3390/antiox15040480
Zhang, Q., Li, H., Yu, F., Gao, M., Wang, Y., Xin, S., Yang, J., Wang, Z., Xiang, L., Ru, Q., et al. (2026) · Chinese Medicine · doi:10.1186/s13020-026-01395-z
Mechanisms of Gui Zhi Fu Ling Formula in Liver Fibrosis: Metabolomics and Gut Microbiota Analysis
Deng, X., Luo, Y., Gao, Y., Su, Y., Xue, H., & Wu, T. (2026) · eFood · doi:10.1002/efd2.70149
The Role of MicroRNA Networks in Alcohol-associated Liver Disease
Park, S. H., & Seo, W. (2026) · Journal of Digestive Cancer Research · doi:10.52927/jdcr.2026.14.1.67
Ullah, A., Khan, M., Zhang, Y., Shafiq, M., Ullah, M., Abbas, A., Ullah, K., Xiangxiang, X., Chen, G., & Diao, Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s586165 · Cited by 1
Tong, J., Wang, Q., Tian, Y., Liu, S., Li, T., Chen, M., Shi, J., Bi, Y., & He-yu, W. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.108935
Integrated Multi-Omics Reveals Synergistic Hepatotoxicity of Ethanol and PFOS Co-Exposure
Stem, A. D., Alayyoub, M., Aalizadeh, R., Nikolopoulou, V., Lisgara, A., Shvartsman, A., Anitha, M., Patterson, A., Coble, R., Rushing, B., et al. (2026) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2026.112101 · Cited by 1
Sun, Y., Yao, S., Cui, Y., Yiyu, N. I., Liu, M., Zhao, D., Yu, S., & Wang, S. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.71829
Multiomics characterization of an alcohol-induced hepatocellular carcinoma mouse model
Oh, S. H., Park, S. B., Kang, J., Shin, S., Kim, G.-Y., Bong, Y., Gu, M., Lee, Y.-S., Gao, B., & Seo, W. (2026) · Lab Animal · doi:10.1038/s41684-026-01724-7
Self-citationLi, Z., 乔杰, & Qiu, J. (2026) · Purinergic Signalling · doi:10.1007/s11302-026-10159-1
Metadata
- Authors
- Mackowiak, B., Fu, Y., Maccioni, L., & Gao, B.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Gao, Bin
- Venue
- Journal of Clinical Investigation
- Published
- 2024-02-01
- Volume
- 134
- Issue
- 3
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC10836812
- OpenAlex
- W4391540982
- Cited by
- 359
- References
- 202
- Citations by year
- 2026: 129 · 2025: 160 · 2024: 70
- FWCI
- 26.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- alcoholic liver disease, alcoholic steatohepatitis, alcoholic cirrhosis, pathogenesis, therapeutic target, multi-omics, preclinical models, metabolic dysfunction, disease heterogeneity, translational research
- MeSH terms
- Ethanol, Fatty Liver, Carcinoma, Hepatocellular, Humans, Liver, Liver Cirrhosis, Liver Diseases, Alcoholic, Liver Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.